CHO Pharma, Inc. (TPEX:6586)

CHO Pharma Statistics

Total Valuation

CHO Pharma has a market cap or net worth of TWD 14.47 billion. The enterprise value is 12.42 billion.

Market Cap	14.47B
Enterprise Value	12.42B

Important Dates

The next estimated earnings date is Friday, August 7, 2026.

Earnings Date	Aug 7, 2026
Ex-Dividend Date	n/a

Share Statistics

CHO Pharma has 214.01 million shares outstanding.

Current Share Class	214.01M
Shares Outstanding	214.01M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	18.51%
Owned by Institutions (%)	16.84%
Float	143.52M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	10,109.79
PB Ratio	5.87
P/TBV Ratio	7.08
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-42.83
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-43.00

Financial Position

The company has a current ratio of 19.47, with a Debt / Equity ratio of 0.01.

Current Ratio	19.47
Quick Ratio	18.96
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.05
Interest Coverage	-802.56

Financial Efficiency

Return on equity (ROE) is -11.13% and return on invested capital (ROIC) is -7.75%.

Return on Equity (ROE)	-11.13%
Return on Assets (ROA)	-7.47%
Return on Invested Capital (ROIC)	-7.75%
Return on Capital Employed (ROCE)	-13.23%
Weighted Average Cost of Capital (WACC)	7.09%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	47
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +65.96% in the last 52 weeks. The beta is 0.52, so CHO Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.52
52-Week Price Change	+65.96%
50-Day Moving Average	47.57
200-Day Moving Average	36.10
Relative Strength Index (RSI)	62.10
Average Volume (20 Days)	1,093,168

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, CHO Pharma had revenue of TWD 1.43 million and -290.01 million in losses. Loss per share was -1.36.

Revenue	1.43M
Gross Profit	1.07M
Operating Income	-325.84M
Pretax Income	-290.01M
Net Income	-290.01M
EBITDA	-313.46M
EBIT	-325.84M
Loss Per Share	-1.36

Balance Sheet

The company has 2.06 billion in cash and 14.59 million in debt, with a net cash position of 2.05 billion or 9.56 per share.

Cash & Cash Equivalents	2.06B
Total Debt	14.59M
Net Cash	2.05B
Net Cash Per Share	9.56
Equity (Book Value)	2.46B
Book Value Per Share	11.51
Working Capital	2.01B

Cash Flow

In the last 12 months, operating cash flow was -279.57 million and capital expenditures -9.30 million, giving a free cash flow of -288.87 million.

Operating Cash Flow	-279.57M
Capital Expenditures	-9.30M
Depreciation & Amortization	12.38M
Net Borrowing	-14.31M
Free Cash Flow	-288.87M
FCF Per Share	-1.35

Margins

Gross Margin	74.49%
Operating Margin	-22,770.16%
Pretax Margin	-20,265.97%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

CHO Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-2.00%
FCF Yield	-2.00%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

CHO Pharma has an Altman Z-Score of 49.48 and a Piotroski F-Score of 2.

Altman Z-Score	49.48
Piotroski F-Score	2